Hostname: page-component-848d4c4894-p2v8j Total loading time: 0 Render date: 2024-05-11T19:46:22.925Z Has data issue: false hasContentIssue false
  • English
  • Français

Development and Validation of a Clostridium difficile Infection Risk Prediction Model

Part of: BARRY FARR AWARD RECIPIENTS

Published online by Cambridge University Press:  02 January 2015

Erik R. Dubberke ,
Yan Yan ,
Kimberly A. Reske ,
Anne M. Butler ,
Joshua Doherty ,
Victor Pham  and
Victoria J. Fraser
Erik R. Dubberke*
Affiliation:
Washington University School of Medicine, St. Louis, Missouri
Yan Yan
Affiliation:
Washington University School of Medicine, St. Louis, Missouri
Kimberly A. Reske
Affiliation:
Washington University School of Medicine, St. Louis, Missouri
Anne M. Butler
Affiliation:
Washington University School of Medicine, St. Louis, Missouri
Joshua Doherty
Affiliation:
Barnes-Jewish Hospital, St. Louis, Missouri
Victor Pham
Affiliation:
Barnes-Jewish Hospital, St. Louis, Missouri
Victoria J. Fraser
Affiliation:
Washington University School of Medicine, St. Louis, Missouri
*
Box 8051, 660 South Euclid, St. Louis, MO 63110 (edubberk@dom.wustl.edu)
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To develop and validate a risk prediction model that could identify patients at high risk for Clostridium difficile infection (CDI) before they develop disease.

Design and Setting.

Retrospective cohort study in a tertiary care medical center.

Patients.

Patients admitted to the hospital for at least 48 hours during the calendar year 2003.

Methods.

Data were collected electronically from the hospital's Medical Informatics database and analyzed with logistic regression to determine variables that best predicted patients' risk for development of CDI. Model discrimination and calibration were calculated. The model was bootstrapped 500 times to validate the predictive accuracy. A receiver operating characteristic curve was calculated to evaluate potential risk cutoffs.

Results.

A total of 35,350 admitted patients, including 329 with CDI, were studied. Variables in the risk prediction model were age, CDI pressure, times admitted to hospital in the previous 60 days, modified Acute Physiology Score, days of treatment with high-risk antibiotics, whether albumin level was low, admission to an intensive care unit, and receipt of laxatives, gastric acid suppressors, or antimotility drugs. The calibration and discrimination of the model were very good to excellent (C index, 0.88; Brier score, 0.009).

Conclusions.

The CDI risk prediction model performed well. Further study is needed to determine whether it could be used in a clinical setting to prevent CDI-associated outcomes and reduce costs.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 32 , Issue 4 , April 2011 , pp. 360 - 366
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Dubberke, ER, Reske, KA, Olsen, MA, McDonald, LC, Fraser, VJ. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis 2008;46(4):497–504.Google Scholar
2. Dubberke, ER, Butler, AM, Reske, KA, et al. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis 2008;14(7):1031–1038.10.3201/eid1407.070867Google Scholar
3. Kyne, L, Hamel, MB, Polavaram, R, Kelly, CR Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile . Clin Infect Dis 2002;34(3):346–353.Google Scholar
4. Loo, VG, Libman, MD, Miller, MA, et al. Clostridium difficile: a formidable foe. CMAJ 2004;171(1):47–48.Google Scholar
5. Loo, VG, Poirier, L, Miller, MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353(23):2442–2449.Google Scholar
6. Muto, CA, Pokrywka, M, Shutt, K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26(3):273–280.Google Scholar
7. Pépin, J, Valiquette, L, Alary, M-E, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003; a changing pattern of disease severity. CMAJ 2004;171(5):466–472.10.1503/cmaj.1041104Google Scholar
8. Pépin, J, Alary, M-E, Valiquette, L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40(11):1591–1597.Google Scholar
9. Pépin, J, Valiquette, L, Cossette, B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005;173(9):1037–1042.10.1503/cmaj.050978Google Scholar
10. Dial, S, Alrasadi, K, Manoukian, C, Huang, A, Menzies, D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171(1):33–38.10.1503/cmaj.1040876Google Scholar
11. Dial, S, Delaney, JA, Barkun, AN, Suissa, S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294(23):2989–2995.Google Scholar
12. Dial, S, Delaney, JA, Schneider, V, Suissa, S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006;175(7):745–748.10.1503/cmaj.060284Google Scholar
13. Dubberke, ER, Reske, KA, Olsen, MA, et al. Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C difficile-associated disease. Arch Intern Med 2007;167(10):1092–1097.10.1001/archinte.167.10.1092Google Scholar
14. Dubberke, ER, Reske, KA, Yan, Y, Olsen, MA, McDonald, LC, Fraser, VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007;45(12):1543–1549.Google Scholar
15. Gerding, DN, Johnson, S, Peterson, LR, Mulligan, ME, Silva, J Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16(8):459–477.Google Scholar
16. Kyne, L, Sougioultzis, S, McFarland, LV, Kelly, CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002;23(11):653–659.Google Scholar
17. Pépin, J, Saheb, N, Coulombe, M-A, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41(9):1254–1260.10.1086/496986Google Scholar
18. McDonald, LC, Owings, M, Jernigan, DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12(3):409–415.Google Scholar
19. Muto, CA, Blank, MK, Marsh, JW, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive “bundle” approach. Clin Infect Dis 2007;45(10):1266–1273.10.1086/522654Google Scholar
20. Peterson, CA, Calderon, RL. Trends in enteric disease as a cause of death in the United States, 1989-1996. Am J Epidemiol 2003;157(1):58–65.Google Scholar
21. Johnson, S, Gerding, DN, Olson, MM, et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990;88(2):137–140.Google Scholar
22. Kaatz, GW, Gitlin, SD, Schaberg, DR, et al. Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol 1988;127(6):1289–1294.10.1093/oxfordjournals.aje.a114921Google Scholar
23. Mayfield, JL, Leet, T, Miller, J, Mundy, LM. Environmental control to reduce transmission of Clostridium difficile . Clin Infect Dis 2000;31(4):995–1000.10.1086/318149Google Scholar
24. McMullen, KM, Zack, J, Coopersmith, CM, Kallef, M, Dubberke, E, Warren, DK. Use of hypochlorite solution to decrease rates of Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2007;28(2):205–207.Google Scholar
25. D'Agostino, RB, Belanger, AJ, Markson, EW, Kelly-Hayes, M, Wolf, PA. Development of health risk appraisal functions in the presence of multiple indicators: the Framingham Study nursing home institutionalization model. Stat Med 1995;14(16):1757–1770.Google Scholar
26. Harrell, FE Jr, Margolis, PA, Gove, S, et al. Development of a clinical prediction model for an ordinal outcome: the World Health Organization Multicentre Study of Clinical Signs and Etiological Agents of Pneumonia, Sepsis and Meningitis in Young Infants. Stat Med 1998;17(8):909–944.Google Scholar
27. Garey, KW, Dao-Tran, TK, Jiang, ZD, Price, MP, Gentry, LO, DuPont, HL. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect 2008;70(2):142–147.10.1016/j.jhin.2008.06.026Google Scholar
28. Tanner, J, Khan, D, Anthony, D, Paton, J. Waterlow score to predict patients at risk of developing Clostridium difficile-associated disease. J Hosp Infect 2009;71(3):239–244.Google Scholar
29. Thorn, KA, Shardell, MD, Osih, RB, et al. Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points. Infect Control Hosp Epidemiol 2008;29(11):1048–1053.Google Scholar
30. D'Agostino, RB, Griffith, JL, Schmidt, CH, Terrin, N. Measures for evaluating model performance. In: Proceedings of the Biometrics Section. Alexandria, VA: American Statistical Association, 1997:253–258.Google Scholar
31. Cook, NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 2008;54(1):17–23.10.1373/clinchem.2007.096529Google Scholar
32. Efron, B, Tibshirani, R. An introduction to the bootstrap. New York: Chapman & Hall, 1993.10.1007/978-1-4899-4541-9Google Scholar
33. Bilgrami, S, Feingold, JM, Dorsky, D, et al. Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;23(10):1039–1042.Google Scholar
34. Chakrabarti, S, Lees, A, Jones, SG, Milligan, DW. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant 2000;26(8):871–876.10.1038/sj.bmt.1702627Google Scholar
35. Tomblyn, M, Gordon, L, Singhai, S, et al. Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. Bone Marrow Transplant 2002;30(8):517–519.Google Scholar
36. Yuen, K-Y, Woo, PCY, Liang, RHS, et al. Clinical significance of alimentary tract microbes in bone marrow transplant recipients. Diagn Microbiol Infect Dis 1998;30(2):75–81.Google Scholar
37. Dubberke, ER, Gerding, DN, Classen, D, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008;29(suppl 1):S81–S92.Google Scholar